

To: Participating AmeriHealth Caritas Florida Providers

Date: October 18, 2021

Subject: Changes to Preferred Drug List (PDL)

Please reference the attached Florida Pharmaceutical & Therapeutics Committee Meeting report from September 24, 2021 for changes to the PDL effective October 1, 2021.

You can find additional information on the drug formularies by visiting www.amerhealthcaritasfl.com and/or https://ahca.myflorida.com/Medicaid/Prescribed_Drug/pharm_thera/index.shtml.

If you have questions about this communication, please contact your Provider Account Executive or the Provider Services department at **1-800-617-5727**.

11631 Kew Gardens Avenue, Suite 200, Palm Beach Gardens, FL 33410

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally protected. This information is intended only for the use of the individuals or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

From the September 24, 2021
 Florida Pharmaceutical & Therapeutics Committee Meeting
 (Changes Effective October 1, 2021)

ANALGESICS, NARCOTICS LONG	PDL Status Before Meeting	PDL Status After Meeting	Comments
METHADONE CONC SYRINGE (ORAL)	NA	Non-PDL	
ANALGESICS, NARCOTICS SHORT			
QDOLO (ORAL)	NA	Non-PDL	
ANTICONVULSANTS			
ELEPSIA XR TABLET (ORAL)	NA	Non-PDL	
ANTIFUNGALS, ORAL			
NOXAFIL TABLET (ORAL)	Non-PDL	PDL	
CHEMOTHERAPY RESCUE			
COSELA (INTRAVEN)	NA	Non-PDL	
CYTOKINE AND CAM ANTAGONISTS			
SKYRIZI PEN (SUBCUTANEOUS)	NA	Non-PDL	
HYPOGLYCEMICS, SGLT2			
SYNJARDY (ORAL)	Non-PDL	PDL	
XIGDUO XR (ORAL)	Non-PDL	PDL	
LAXATIVES & CATHARTICS			
ALVIMOPAN CAPSULE (ORAL)	NA	Non-PDL	
SUTAB (ORAL)	NA	Non-PDL	
MULTIPLE SCLEROSIS AGENTS			
BAFIERTAM CAPSULE DR (ORAL)	NA	Non-PDL	
MAYZENT DOSE PACK (ORAL)	NA	Non-PDL	
PONVORY STARTER PACK (ORAL)	NA	Non-PDL	
PONVORY TABLET (ORAL)	NA	Non-PDL	
NSAIDS			
NAPROXEN SUSPENSION (AG) (ORAL)	Non-PDL	PDL	
NAPROXEN SUSPENSION (ORAL)	Non-PDL	PDL	
NSAIDS, INJECTABLE			
ANJESO (INTRAVEN)	NA	PDL	
CALDOLOR (INTRAVEN)	NA	Non-PDL	
OCTREOTIDES & RELATED			
BYNFEZIA (SUBCUTANEOUS)	NA	Non-PDL	
MYCAPSSA (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - HEMATOLOGIC			
INQOVI (ORAL)	NA	Non-PDL	
ONUREG (ORAL)	NA	Non-PDL	
UKONIQ (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - LUNG			
GAVRETO (ORAL)	NA	Non-PDL	
LUMAKRAS (ORAL)	NA	Non-PDL	
TEPMETKO (ORAL)	NA	Non-PDL	

ONCOLOGY, ORAL - OTHER			
TRUSELTIQ (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - PROSTATE			
ORGOVYX (ORAL)	NA	Non-PDL	
ONCOLOGY, ORAL - RENAL CELL			
FOTIVDA (ORAL)	NA	Non-PDL	
SUTENT (ORAL)	PDL	Non-PDL	
OPHTHALMICS, ANTI-INFLAMMATORIES			
FML S.O.P. (OPHTHALMIC)	PDL	Non-PDL	
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR			
EYSUVIS (OPHTHALMIC)	NA	Non-PDL	
PROGESTATIONAL AGENTS			
PROMETRIUM (ORAL)	PDL	Non-PDL	
STEROIDS, TOPICAL VERY HIGH			
CLOBETEX KIT (MISCELL)	NA	Non-PDL	
STIMULANTS AND RELATED AGENTS			
QELBREE (ORAL)	NA	Non-PDL	
UTERINE DISORDER TREATMENTS			
MYFEMBREE (ORAL)	NA	PDL	Clinical PA

NA = NOT APPLICABLE (FOR NEW PRODUCTS)